.

L46 - WHITEFIELD LAB HOME VISIT

SY NO. 18/1B, K R PURAM, HOBLI, SREE SAI
HARSHA TOWER, WHITE FIELD

Name : Mr. ARDHENDU PAL Collected : 3/6/2017 9:42:00AM

Received : 3/6/2017 9:42:39AM
Lab No. : 136618520 Age: 23 Years Gender: Male Reported : 7/6/2017 6:41:54PM
A/c Status : P Ref By : SELF Report Status : Final

Test Name Results Units Bio. Ref. Interval

LIPID PROFILE, COMPLETE, SERUM @
(Spectrophotometry, Agarose gel Electrophoresis)

Sample Appearance Clear

Cholesterol Total 156.00 mg/dL <200.00

Triglycerides 146.00 mg/dL <150.00

HDL Cholesterol 36.90 mg/dL >40.00

LDL Cholesterol 89.90 mg/dL <100.00
VLDL Cholesterol 29.20 mg/dL <30.00
Non HDL Cholesterol 119.10 mg/dL <130.00
Cholesterol:HDL Ratio 4.23 3.30 - 4.40

Lipoprotein Electrophoresis .

HDL 20.50 % 15.1 - 39.9

LDL 48.40 % 42.3 - 69.5
VLDL 31.10 % 2.0 - 31.2
Chylomicrons Absent Nil

PatientReportSCSuperPanel.HBELECTRO_SC (Version: 7)

*136618520* Page 1 of 4
.

L46 - WHITEFIELD LAB HOME VISIT

SY NO. 18/1B, K R PURAM, HOBLI, SREE SAI
HARSHA TOWER, WHITE FIELD

Name : Mr. ARDHENDU PAL Collected : 3/6/2017 9:42:00AM

Received : 3/6/2017 9:42:39AM
Lab No. : 136618520 Age: 23 Years Gender: Male Reported : 7/6/2017 6:41:54PM
A/c Status : P Ref By : SELF Report Status : Final

Test Name Results Units Bio. Ref. Interval

Interpretation
-----------------------------------------------------------------------------------
| NATIONAL LIPID | TOTAL | TRIGLYCERIDE | LDL CHOLESTEROL |NON HDL |
| ASSOCIATION | CHOLESTEROL | in mg/dL | in mg/dL |CHOLESTEROL |
| RECOMMENDATIONS | in mg/dL | | |in mg/dL |
| (NLA-2014) | | | | |
|-------------------|---------------|--------------|-----------------|--------------|
| Optimal | <200 | <150 | <100 | <130 |
|-------------------|---------------|--------------|-----------------|--------------|
| Above Optimal | - | - | 100- 129 | 130 - 159 |
|-------------------|---------------|--------------|-----------------|--------------|
| Borderline High | 200-239 | 150-199 | 130-159 | 160 - 189 |
|-------------------|---------------|--------------|-----------------|--------------|
| High | >=240 | 200-499 | 160-189 | 190 - 219 |
|-------------------|---------------|--------------|-----------------|--------------|
| Very High | - | >=500 | >=190 | >=220 |
-----------------------------------------------------------------------------------

----------------------------------------
| REMARKS | CHOLESTEROL:HDL Ratio |
| | |
|----------------|------------------------|
| Low risk | 3.3 - 4.4 |
|----------------|------------------------|
| Average risk | 4.5 - 7.1 |
|----------------|------------------------|
| Moderate risk | 7.2 - 11.0 |
|----------------|------------------------|
| High risk | >11.0 |
-----------------------------------------

Note
1. Measurements in the same patient can show physiological& analytical variations. Three serial samples
1 week apart are recommended for Total Cholesterol, Triglycerides, HDL& LDL Cholesterol.
2. NLA-2014 identifies Non HDL Cholesterol(an indicator of all atherogenic lipoproteins such as LDL ,
VLDL, IDL, Lpa, Chylomicron remnants)along with LDL-cholesterol as co- primary target for cholesterol
lowering therapy. Note that major risk factors can modify treatment goals for LDL &Non HDL.
3. Apolipoprotein B is an optional, secondary lipid target for treatment once LDL & Non HDL goals have
been achieved.
4. Additional testing for Apolipoprotein B, hsCRP, Lp(a ) & LP-PLA2 should be considered among patients
with moderate risk for ASCVD for risk refinement

Comment
A variety of genetic conditions are associated with accumulation in plasma of specific class of lipoprotein
particles. The critical first step in managing lipid disorder is to determine the class or classes of lipoprotein that
are increased or decreased in a patient. Frederickson classification can be helpful in this regard. The
hyperlipidemic status should be evaluated to determine if it is a primary lipoprotein disorder or secondary to
metabolic disease. The diagnosis of primary hyperlipidemia is made after secondary causes have been ruled
PatientReportSCSuperPanel.HBELECTRO_SC (Version: 7)

*136618520* Page 2 of 4
.

L46 - WHITEFIELD LAB HOME VISIT

SY NO. 18/1B, K R PURAM, HOBLI, SREE SAI
HARSHA TOWER, WHITE FIELD

Name : Mr. ARDHENDU PAL Collected : 3/6/2017 9:42:00AM

Received : 3/6/2017 9:42:39AM
Lab No. : 136618520 Age: 23 Years Gender: Male Reported : 7/6/2017 6:41:54PM
A/c Status : P Ref By : SELF Report Status : Final

Test Name Results Units Bio. Ref. Interval

out. It is important to diagnose primary lipid disorder since the underlying etiology has significant effect on
development of CHD, on response to drug therapy, and on the management of other family members. Type II b
is the most commonly inherited lipid disorder, occurring in approximately 1 in 200 persons. Familial
hypertriglyceridemia (FHTG) is a relatively common (1:500) autosomal dominant disorder of unknown etiology.
It is important to consider & rule out secondary causes of hypertriglyceridemia (Obesity, Type 2 DM,
Alcoholism, Renal failure, Cushing's syndrome etc.) before making the diagnosis of FHTG.

------------------------------------------------------------------------------------------------
| FREDRICKSON CLASSIFICATION |
|------------------------------------------------------------------------------------------------|
| Type of |Molecular |Estimated |Lipoprotein |Cholesterol,|Triglyceride|Serum |
|Hyperlipoproteinemia|defect |incidence |elevated |Total(mg/dL)|(mg/dL) |Appearance |
|--------------------|-----------|-----------|------------|------------|------------|------------|
| I |Lipoprotien|1 in |Chylomicrons|+ to ++ | ++++ |Milky |
|Familial |lipase |1,000,000 | |200-400 |>3000 | |
|Chylomicronemia |deficiency;| | | | | |
|Syndrome |Apo C II | | | | | |
| |deficiency | | | | | |
|--------------------|-----------|-----------|------------|------------|------------|------------|
| IIa |Mutation in|1 in 500 | LDL | +++ |Normal |Clear |
|Familial |LDL | | |300-1000 | | |
|Hypercholesterolemia|receptor, | | | | | |
| |Apo B 100 | | | | | |
|--------------------|-----------|-----------|------------|------------|------------|------------|
| II b |Unknown |1 in 200 |LDL & VLDL |++ to +++ | ++ |Clear to |
|Familial Combined | | | |280-350 |200-500 |slightly |
|Hyperlipidemia | | | | | |turbid |
|--------------------|-----------|-----------|------------|------------|------------|------------|
| III |Genetic |1 in 10,000|Chylomicron |++ to +++ |++ to +++ |Clear to |
|Familial Dysbeta |variation | |and VLDL |300- 500 |200- 900 |slightly |
|lipoproteinemia or |in APO E | |remnant | | |turbid |
|Familial broadbeta | | | (IDL) | | | |
|disease | | | | | | |
|--------------------|-----------|-----------|------------|------------|------------|------------|
| IV |Unknown |1 in 500 | VLDL |Usually | ++ |Turbid |
|Familial | | | |<270 |200-1000 | |
|hypertriglyceridemia| | | | | | |
|--------------------|-----------|-----------|------------|------------|------------|------------|
| V |Unknown |1 in 500 |Chylomicron |++ to +++ | ++++ |Milky |
|Familial | | |& VLDL |<500 |<3000 | |
|hypertriglyceridemia| | | | | | |
------------------------------------------------------------------------------------------------

Dr Himangshu Mazumdar Dr. Nimmi Kansal

MD (Biochemistry) MD (Biochemistry)
Consultant Biochemist HOD Biochem & IA

PatientReportSCSuperPanel.HBELECTRO_SC (Version: 7)

*136618520* Page 3 of 4
.

L46 - WHITEFIELD LAB HOME VISIT

SY NO. 18/1B, K R PURAM, HOBLI, SREE SAI
HARSHA TOWER, WHITE FIELD

Name : Mr. ARDHENDU PAL Collected : 3/6/2017 9:42:00AM

Received : 3/6/2017 9:42:39AM
Lab No. : 136618520 Age: 23 Years Gender: Male Reported : 7/6/2017 6:41:54PM
A/c Status : P Ref By : SELF Report Status : Final

Test Name Results Units Bio. Ref. Interval

-------------------------------End of report --------------------------------

PatientReportSCSuperPanel.HBELECTRO_SC (Version: 7)

*136618520* Page 4 of 4